ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / A / news
WAT (72) MTD (78) RVTY (65) AVTR (56) ⌘ Pro Terminal →

Why A Stock slipped -1.65% Today — RQD Quant Desk Flash

$171.99 -1.65% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $171.89

Agilent Technologies Inc. (A) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (52% profit margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $49.30B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on A Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is A stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Agilent Technologies Inc. (NYSE: A) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $171.99 (-1.65% 1D, market cap $49.30B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, A ranks #55 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does A compare to WAT and MTD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), A carries a Roarable B (72/100 RQD), trailing P/E of 39.2x, gross margin of 52.4%, and ROIC of 15.3%. By comparison, WAT (Waters Corporation) holds a B grade (72/100 RQD, P/E 73.4x, ROIC 16.8%, cap $45.46B) and MTD (Mettler-Toledo International Inc.) posts a B+ grade (78/100 RQD, P/E 39.6x, ROIC 30.4%, cap $33.56B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for A?
▼

Per A's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001090872), Agilent Technologies Inc. generated $6.95B in revenue (+6.7% YoY), $1.30B in net income, and $1.15B in free cash flow against $12.81B in total assets and $2.66B in total debt. Key quantitative strengths: Strong cash generator (52% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $171.89 (-0.06%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 16.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B
Cash (15)Whales (16)SEC (18)Macro (11)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$216 Bull$183 Base$141 Bear
📬 FREE A RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for A)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY A SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 6.50 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (22% of score)

20D Institutional Volume Accumulation (±5.5% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)

Macro rate sensitivity & RSI-14 (52.5) create a -9 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
80
Grade A-$174.00+2.2% Next Q
Q2 (-2Q)
77
Grade B+$177.75+2.1% Next Q
Q3 (-1Q)
75
Grade B+$181.48-5.2% Next Q
Current
72
Grade B$171.99+7% Hist 90D α
Trajectory: A- (80) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the A Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, A faces multiple-compression risk if 39.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($165.49) or 200D SMA ($136.64) invalidates the momentum regime and cuts Target Base ($182.83) toward Bear Floor ($141.03).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $A• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “A Beats Next Quarter EPS Consensus (Jan 29, 2027) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why A Stock slipped -1.65% Today — RQD Quant Desk Flash

Agilent Technologies Inc. (A) slipped -1.65% to $171.99, trading at 85% of its 52-week range ($108.35 – $182.99). High-quality cash engine (52% profit margin, 15% return on capital) with steady institutional support.

  • ▸Technical Tape: Trading at 85% of its 52-week range ($108.35 – $182.99) with RSI-14 at 52.5 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±5.5% around $171.99 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable B (Buy) backed by 52.4% gross margin and $1.2B annual free cash flow.
Live A Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (A Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
A // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +53.32%▲ ASCENDING CHANNEL
2026-11-03O $181.2H $181.2L $172.0C $172.0VOL 2.76M
RES: $192.2SUP: $157.9SMA50: $165.5SMA200: $136.6
$188.2$166.6$144.9$123.3$101.6RES $192.2SUP $157.9$172.02026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

A Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 A Butterfly Map → + Track A →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
29.9%/yr Implied 5Y Growth

vs. +6.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on A today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for A. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for A today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (A)

Health Care Rank #55 of 1016 ⚔️ WAT vs A Full Matrix →

1. Head-to-Head Health Care Peer Comparison (A vs. WAT, MTD, RVTY, AVTR)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Agilent Technologies Inc. (A) ranks #55 by composite RQD confidence (72/100, grade B) and #39 by equity capitalization ($49.30B). Within this direct 5-issuer industry benchmark cohort, A leads on earnings valuation at 39.2x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with A at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
A ACTIVE
Agilent Technologies Inc.
B 72/100 39.2x 52.4% 15.3% -1.65% $49.30B Benchmark Subject
WAT
Waters Corporation
B 72/100 73.4x 59.3% 16.8% -2.85% $45.46B /wat-vs-a →
MTD
Mettler-Toledo International Inc.
B+ 78/100 39.6x 59.4% 30.4% +0.20% $33.56B /mtd-vs-a →
RVTY
Revvity Inc.
C 65/100 76.7x — 3.1% -3.44% $17.52B /rvty-vs-a →
AVTR
Avantor Inc.
D+ 56/100 — 32.7% -2.1% -2.74% $10.88B /avtr-vs-a →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-10-31 • CIK 0001090872

In its most recent audited fiscal period (FY2025, filed 2025-10-31), Agilent Technologies Inc. (A) reported GAAP revenue of $6.95B (+6.7% vs. FY2024 revenue of $6.51B , and +1.7% cumulative change since FY2023) , GAAP net income of $1.30B, operating cash flow of $1.56B, and free cash flow of $1.15B (-16.1% YoY). On the balance sheet, A closed FY2025 with $12.81B in total assets against $2.66B in total debt (Altman Z-Score: 6.50, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-10-31 $6.95B $1.30B $1.56B $1.15B $12.81B $2.66B
FY2024 (FY) 2024-10-31 $6.51B $1.29B $1.75B $1.37B $11.91B $2.65B
FY2023 (FY) 2023-10-31 $6.83B $1.24B $1.77B $1.46B $28.09B $6.57B

3. A Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is A stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Agilent Technologies Inc. (NYSE: A) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $171.99 (-1.65% 1D, market cap $49.30B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, A ranks #55 in composite RQD confidence.

How does A compare to WAT and MTD in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), A carries a Roarable B (72/100 RQD), trailing P/E of 39.2x, gross margin of 52.4%, and ROIC of 15.3%. By comparison, WAT (Waters Corporation) holds a B grade (72/100 RQD, P/E 73.4x, ROIC 16.8%, cap $45.46B) and MTD (Mettler-Toledo International Inc.) posts a B+ grade (78/100 RQD, P/E 39.6x, ROIC 30.4%, cap $33.56B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for A?

Per A's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001090872), Agilent Technologies Inc. generated $6.95B in revenue (+6.7% YoY), $1.30B in net income, and $1.15B in free cash flow against $12.81B in total assets and $2.66B in total debt. Key quantitative strengths: Strong cash generator (52% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is A trading relative to its 50-day, 200-day, and 52-week technical levels?

A last traded at $171.99 (-1.65% on volume of 1,860,871 shares), positioning the stock +3.93% above its 50-day simple moving average ($165.49) and +25.87% above its 200-day simple moving average ($136.64). Across its 52-week range of $108.35 to $182.99, A sits at the 85.3% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($162.53 to $181.45).

Direct Sub-Reports: A RQD Cockpit A 12M Forecast A Earnings & Move A Dividends & DRIP A Insiders & 13F A Whale Options A Profit Sankey A News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ SEC XBRL & RQD VERIFIED

A — Agilent Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-10-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Agilent Technologies Inc. (A) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $171.99 (-1.65% 1D, market capitalization $49.30B).

  • Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 15.3%, gross margin of 52.4%, operating margin of 21.3%, and free cash flow yield of 2.26%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (12/20): Incorporates a 0.91x equity beta, Altman Z-Score of 6.50, Piotroski F-Score of 9/9, and Debt/Equity of 0.36x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Agilent Technologies Inc. Is listed on the NYSE and classified under the Health Care sector. It operates in the Biotechnology: Laboratory Analytical Instruments industry. The company generated revenue of $6.95B in FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-10-31), Agilent Technologies Inc. (A) reported $6.95B in annual revenue (up from $6.51B in FY2024, +6.7% YoY) and $1.30B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.83B revenue, $1.24B net income) through FY2025, A scaled operating cash flow to $1.56B and free cash flow to $1.15B, backed by $12.81B in total assets against $2.66B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 72/100): Strong cash generator (52% profit margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $108.35 – $182.99 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 39.2x trailing P/E and 28.4x EV/EBITDA against 21.3% operating margins and a 0.91x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

An investor should note that the absence of mapped links means this brief cannot assess second-order ripple effects from supplier or customer disruptions.

  • Key Question #1: Can A sustain or expand its 21.3% operating margin and 15.3% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.95B and free cash flow of $1.15B, how will capital allocation balance growth reinvestment against $2.66B in total debt?
  • Key Question #3: How sensitive is A's 36.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.91x)?

A Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Agilent Technologies Inc. (A) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to A Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

A Bull vs. Bear Conversation Board — What's Your Call at $171.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON A 🐻 33% BEARISH CONVICTION
1. Pick Your Side on A:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $222.08 (+27.0%)
📌 Pinned Debate

Strong forensic balance sheet (Altman Z 6.5, Piotroski F 9/9) and the highest-scoring 13F flow pillar (18/20) signal financial resilien

Strong forensic balance sheet (Altman Z 6.5, Piotroski F 9/9) and the highest-scoring 13F flow pillar (18/20) signal financial resilience and institutional support.. When you look under the hood at A, Fundamental Cash Engine is 15/20 with 52.4% gross margins and 15.3% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $182.99. My 12M target is $222.08.

RetailWhale_TX 🐂 BULL

@CreditSpread_Watch Shorting a 16/20 institutional whale-flow stock at $174.87 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $145.14 (-17.0%)
Spot @ $174.87

A trailing P/E of 39.2 and a free-cash-flow yield of just 2.26% leave little valuation cushion for the stock's middling macro-regime fi

A trailing P/E of 39.2 and a free-cash-flow yield of just 2.26% leave little valuation cushion for the stock's middling macro-regime fit.. Look at the math on A: paying 39.2x trailing P/E for 15.3% ROIC and 21.3% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $153.89 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%